Literature DB >> 10068276

Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy.

I B Weinstein1, M Begemann, P Zhou, E K Han, A Sgambato, Y Doki, N Arber, M Ciaparrone, H Yamamoto.   

Abstract

The development of a malignant tumor involves the progressive acquisition of mutations and epigenetic abnormalities in multiple genes that have highly diverse functions. Some of these genes code for pathways of signal transduction that mediate the action of growth factors. The enzyme protein kinase C plays an important role in these events and in the process of tumor promotion. Therefore, we examined the effects of three inhibitors of protein kinase C, CGP 41251, RO 31-8220, and calphostin C, on human glioblastoma cells. These compounds inhibited growth and induced apoptosis; these activities were associated with a decrease in the level of CDC2 and cyclin B1/CDC2-associated kinase activity. This may explain why the treated cells accumulated in G2-M. In a separate series of studies, we examined abnormalities in cell cycle control genes in human cancer. We have found that cyclin D1 is frequently overexpressed in a variety of human cancers. Mechanistic studies indicate that cyclin D1 can play a critical role in carcinogenesis because: overexpression enhances cell transformation and tumorigenesis; introduction of an antisense cyclin D1 cDNA into either human esophageal or colon cancer cells reverts their malignant phenotype; and overexpression of cyclin D1 can enhance the amplification of other genes. The latter finding suggests that cyclin D1 can enhance genomic instability and, thereby, the process of tumor progression. Therefore, inhibitors of the function of cyclin D1 may be useful in both cancer chemoprevention and therapy. We obtained evidence for the existence of homeostatic feedback loops between cyclins D1 or E and the cell cycle inhibitory protein p27Kip1. On the basis of these and other findings, we hypothesize that, because of their disordered circuitry, cancer cells suffer from "gene addiction" and "gene hypersensitivity," disorders that might be exploited in both cancer prevention and therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 10068276

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  32 in total

1.  Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy.

Authors:  Brian J Park; Zakary L Whichard; Seth J Corey
Journal:  Cancer Lett       Date:  2012-02-02       Impact factor: 8.679

2.  A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes.

Authors:  Sreenath V Sharma; Patrycja Gajowniczek; Inna P Way; Diana Y Lee; Jane Jiang; Yuki Yuza; Marie Classon; Daniel A Haber; Jeffrey Settleman
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

Review 3.  Targeting cancer with small molecule kinase inhibitors.

Authors:  Jianming Zhang; Priscilla L Yang; Nathanael S Gray
Journal:  Nat Rev Cancer       Date:  2009-01       Impact factor: 60.716

4.  Proteomic profiling identified multiple short-lived members of the central proteome as the direct targets of the addicted oncogenes in cancer cells.

Authors:  Tonggang Qi; Wei Zhang; Yun Luan; Feng Kong; Dawei Xu; Guanghui Cheng; Yunshan Wang
Journal:  Mol Cell Proteomics       Date:  2013-10-08       Impact factor: 5.911

5.  Association between the G870A polymorphism of Cyclin D1 gene and glioma risk.

Authors:  Hailiang Zong; Lei Cao; Chong Ma; Jianping Zhao; Xing Ming; Ming Shang; Hongsheng Xu
Journal:  Tumour Biol       Date:  2014-05-20

6.  A tumor-immune mathematical model of CD4+ T helper cell dependent tumor regression by oncogene inactivation.

Authors:  Chinyere I Nwabugwu; Kavya Rakhra; Dean W Felsher; David S Paik
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2013

7.  ELP-dependent expression of MCL1 promotes resistance to EGFR inhibition in triple-negative breast cancer cells.

Authors:  Peter Cruz-Gordillo; Megan E Honeywell; Nicholas W Harper; Thomas Leete; Michael J Lee
Journal:  Sci Signal       Date:  2020-11-17       Impact factor: 8.192

Review 8.  Biology-driven cancer drug development: back to the future.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  BMC Biol       Date:  2010-04-12       Impact factor: 7.431

9.  Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.

Authors:  Jason M Foster; Uppala Radhakrishna; Venkatesh Govindarajan; Joseph H Carreau; Zoran Gatalica; Poonam Sharma; Swapan K Nath; Brian W Loggie
Journal:  World J Surg Oncol       Date:  2010-10-13       Impact factor: 2.754

10.  Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition.

Authors:  Itai Pashtan; Shinji Tsutsumi; Suiquan Wang; Wanping Xu; Len Neckers
Journal:  Cell Cycle       Date:  2008-09-30       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.